HFA 24 - Dr Finn Gustafsson (Rigshospitalet, DK) joined us onsite at the Heart Failure Association Congress to discuss the findings from a subanalysis of the ARIES HeartMate 3 study (NCT04069156).

ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were treated with two different antithrombotic regimens. One treatment group received a Vitamin K antagonist, whereas another group received a vitamin K antagonist with placebo. Findings from AHA 23 showed that the omission of aspirin from an antithrombotic regimen including a VKA in advanced heart failure patients with a left ventricular assist device (LVAD) demonstrated non-inferiority when compared to a regimen that included aspirin.

This subanalysis investigated the patients with a guideline-based prior indication for aspirin in the trial, including those who had undergone PCI or CABG, or had peripheral vascular disease or stroke. This population comprised 41% of the 628 patients randomized in the study. The key findings showed that the primary endpoint of the incidence of death or haemocompatibility-related adverse event within the first 12 months was no different between patients with prior indication to aspirin as compared to those with no indication for aspirin. 

Interview Questions:

1. What is the importance of ARIES HM3?
2. What was your patient population and study design?
3. What are the key findings?
4. How do these findings add to those revealed at AHA?
5. What are your take-home messages?
6. What are the remaining questions?
7. What are the next steps?

Recorded onsite at HFA 24, Lisbon.

Support: This is an independent interview conducted by Radcliffe Cardiology.